Medical Information Request: ZUSDURI™ (mitomycin) for intravesical solution and Pharmacy Preparation

Thank you for your request for additional details regarding the pharmacy preparation of ZUSDURI.

ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Please follow the Instructions for Pharmacy (IFP), that accompany the full prescribing information, for complete information on preparation.

ZUSDURI must be reconstituted with sterile hydrogel under chilled conditions. Reconstituted ZUSDURI has reverse thermal properties with a gelation point of approximately 19°C (66°F) and will appear as a viscous liquid under chilled conditions and a semisolid gel at room temperature.

If reconstituted ZUSDURI is not used immediately, it can be stored under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 7 days. Alternatively, reconstituted ZUSDURI may be stored under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 6 days followed by no more than 24 hours at room temperature, 20°C to 25°C (68°F to 77°F). Avoid excessive heat over 40°C (104°F).

Protect reconstituted ZUSDURI from light.

ZUSDURI is a hazardous drug. Follow applicable special handling and disposal procedures.

Based on ZUSDURI clinical trial experience, below is additional information for the pharmacy preparation process provided by our Clinical Development team and confirmed by our Research and Development team in response to frequently asked questions:

- Place the Chilling Block in the freezer a day before preparation of ZUSDURI admixture. Pharmacy staff should take it out for the preparation and put it back in the freezer at the end of the preparation (Step A1).
- Refer to the Chilling Block as “home”, meaning, whenever you are not using something, put it back in the Chilling Block until use. All the components need to be kept cold during the preparation.
- When using closed system transfer device (CSTD) disinfect the connections before each use with an alcohol wipe for 4-5 seconds.
- Anytime you withdraw hydrogel/ZUSDURI admixture from the vials ensure that the motion is slow, smooth and gentle. Note that there might be some foaming in the syringe while withdrawing hydrogel/ZUSDURI admixture (Steps C1, C2, D2, D3, E1).
- When attaching and detaching the syringe-adaptor assembly from the vial-adaptor assembly - remember to utilize the wings of the syringe adaptor (See FAQ).
- At the end of each transfer to the ZUSDURI vials, pull out a small amount of air (~2 mL) with the attached syringe (through the syringe adaptor), to clear the vial and syringe adaptors from gel. You will hear the air hiss out. Then, after attaching the syringe to the vial again (through the syringe and vial adaptors), inject air into the vial (this will clear any gel that accumulated in the adaptors). (Step C7, D9, E2)
- While withdrawing the hydrogel/ZUSDURI admixture into the syringe(s), make sure not to hold the vial, syringe, or adaptors containing the hydrogel/ZUSDURI admixture in your hand. This may warm the hydrogel/ZUSDURI admixture, causing it to solidify and not flow through the adaptors (Step C1, C2, D2, D3, E1).
- If encountering difficulty withdrawing 14 mL of admixture from the second vial into the second syringe (for transferring it into the first vial), place the second vial back into the Chilling Block for a few minutes in an inverted position. Then, re-attach the syringe and withdraw the leftover admixture from the vial, while holding it upside down. Repeat this step as necessary. (Step E1)

400 Alexander Park Drive, 4th Floor, Princeton, NJ 08540 | 646-768-9780

- Withdraw and transfer at least 28 mL from the second vial to the first vial. Withdrawing a volume greater than 28 mL will ease the administration procedure.
- ZUSDURI admixture storage instructions: Once admixture preparation is completed the admixture should be stored according to the storage conditions:
    - Store reconstituted ZUSDURI at 2°C to 8°C (36°F to 46°F) for up to 7 days. Alternatively, reconstituted ZUSDURI may be stored under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 6 days followed by no more than 24 hours at room temperature, 20°C to 25°C (68°F to 77°F). Avoid excessive heat over 40°C (104°F). Protect from light.
- Once the ZUSDURI admixture is removed out of refrigerated conditions and transferred to room temperature, it should not be returned to storage in refrigerated conditions. It may continue to be kept at room temperature for up to 24 hours.

Please refer to the Full Prescribing Information for ZUSDURI here.

ZUSDURI IMPORTANT SAFETY INFORMATION:

Contraindications

ZUSDURI is contraindicated in patients with perforation of the bladder or in patients with prior hypersensitivity reactions to mitomycin or any component of the product.

Warnings and Precautions

Risks in Patients with Perforated Bladder

ZUSDURI may lead to systemic exposure to mitomycin and severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised. Evaluate the bladder before the intravesical instillation of ZUSDURI and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, ZUSDURI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with ZUSDURI and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZUSDURI and for 3 months following the last dose.

Adverse Reactions

Common Adverse Reactions

The most common (≥10%) adverse reactions, including laboratory abnormalities, that occurred in patients treated with ZUSDURI were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Additional Adverse Reactions Information

Clinically relevant adverse reactions occurring in <10% of patients who received ZUSDURI included increased urinary frequency, fatigue, urinary incontinence, urinary retention, urethral stenosis, genital pain, urinary urgency, genital edema, genital pruritus, genital rash, urethritis, acute kidney injury, balanoposthitis, and nocturia.

Use in Specific Populations

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ZUSDURI and for 1 week following the last dose.

Preparation and Administration Information

ZUSDURI is to be administered by intravesical instillation only. Do not administer ZUSDURI by pyelocalyceal

400 Alexander Park Drive, 4th Floor, Princeton, NJ 08540 | 646-768-9780

instillation or by any other route.

ZUSDURI must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the ZUSDURI Instructions for Pharmacy and administration instructions found in the ZUSDURI Instructions for Administration.

ZUSDURI may discolor urine to a violet to blue color following the instillation procedure. Advise patients for at least 24 hours post-instillation to avoid urine contact with skin, to void urine sitting on a toilet, and to flush the toilet several times after use. Advise patients to wash hands, perineum or glans with soap and water after each instillation procedure.

ZUSDURI is a hazardous drug. Follow applicable special handling and disposal procedures.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

References:

1. ZUSDURI™ (mitomycin) for intravesical solution. Prescribing Information. UroGen Pharma; 2025.
2. ZUSDURI™ (mitomycin) for intravesical solution. Instructions for Pharmacy (IFP)
3. ZUSDURI™ (mitomycin) for intravesical solution. Instructions for Administration (IFA)
4. Chilling Block (Model UCB002). Instructions for Use (IFU)
5. Data on file. UroGen Pharma.

400 Alexander Park Drive, 4th Floor, Princeton, NJ 08540 | 646-768-9780